Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Janka Ryding"'
Autor:
Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerabilit
Externí odkaz:
https://doaj.org/article/7beea784365047a58e0ab0cad4fdf7c7
Autor:
Laurent Vermet, Michaela Golob, Birgit Jaitner, Barry van der Strate, Janka Ryding, Philip Timmerman, Joanne Goodman, Susanne Pihl
Publikováno v:
Bioanalysis, 11(19), 1787-1798. FUTURE SCI LTD
Immunogenicity assays are required to measure antidrug antibodies that are generated against biotherapeutic modalities. As for any ligand-binding assays, critical reagents (CR) play a crucial role in immunogenicity assays, as the robustness and relia
Autor:
Armin Schueler, Michael Stahl, Christian Schwabe, Radmila Kanceva, Vishal Ghori, Janka Ryding, Chris Wynne, Emmanuelle Vincent, Martin Ullmann
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1
Autor:
Chris, Wynne, Christian, Schwabe, Emmanuelle, Vincent, Armin, Schueler, Janka, Ryding, Martin, Ullmann, Vishal, Ghori, Radmila, Kanceva, Michael, Stahl
Publikováno v:
Pharmacology Research & Perspectives
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1
Publikováno v:
Bioanalysis. 9:1395-1406
Biosimilar drug development has brought new challenges to bioanalytical ligand-binding assays used to determine drug concentration, antidrug antibodies and neutralizing antibodies. One particular challenge is how to demonstrate that the antidrug anti
Autor:
Martin Nemansky, Laurent Vermet, Lydia Michaut, Arjen Companjen, Ralf Loebbert, Jenny Hendriks, Susanne Pihl, Janka Ryding
Publikováno v:
Bioanalysis. 6:1409-1413
Long- and short-term stability testing of the analyte is one of the key parameters in bioanalytical method validation in support of pharmacokinetics. However, for immunogenicity testing, the scientific rationale for long- and short-term stability tes
Autor:
Joakim Dillner, David C. G. Skegg, Peter Herbison, Janka Ryding, Thea van Roode, Charlotte Paul, Nigel Dickson
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 18:177-183
Circumcision has been reported to protect against infection with human papillomavirus (HPV) in men, but results have been inconsistent. We followed males in a birth cohort born in Dunedin, New Zealand, in 1972 and 1973 from age 3 to 32 years. Seropos
Autor:
Mahmoud Reza Pourkarim, Elke Wollants, Karen Rans, Severine Vermeire, G. Van Assche, Jannick Verbeeck, Paul Rutgeerts, Maja Noman, Joakim Dillner, Janka Ryding, M. Van Ranst
Publikováno v:
Gut. 57(10)
Background and aims: Anti-alpha 4 integrin therapy with natalizumab is efficacious in refractory Crohn's disease and in multiple sclerosis, but carries an estimated 1/1000 risk of progressive multifocal leukoencephalopathy (PML) caused by reactivatio
Autor:
Janka Ryding, R V Barnabas, Pontus Naucler, Katherine French, Joakim Dillner, Geoffrey P. Garnett
Publikováno v:
Vaccine. 26(41)
We have performed a serological survey of HPV type 16-antibody prevalence by age and sex in Sweden and used it as a basis for modelling the optimal vaccination strategies in this population. Samples of 3,317 subjects were tested for HPV16-specific an
Publikováno v:
The Journal of general virology. 88(Pt 3)
Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigat